NDAINJECTIONINJECTABLEPriority Review
Approved
Oct 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
3/8 — Basic
Priority Review
PROSTIN VR PEDIATRIC (alprostadil) by Pfizer is prostaglandin receptor agonists [moa]. First approved in 1981.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROSTIN VR PEDIATRIC (alprostadil) is a prostaglandin analog that acts as a prostaglandin receptor agonist, administered via injection. It is used to maintain patent ductus arteriosus (PDA) in neonates with certain congenital heart defects pending surgical intervention. The drug works by relaxing vascular smooth muscle and inhibiting platelet aggregation to keep the ductus arteriosus open.
LOE Approaching
This niche pediatric injectable is approaching loss of exclusivity with moderate competitive pressure (30%), suggesting a stabilizing commercial footprint with limited growth opportunities for team expansion.
Mechanism of Action
Prostaglandin Receptor Agonists
Pharmacologic Class:
Prostaglandin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Alprostadil in Maculopathy Study (AIMS)
Started Jul 2006
37 enrolled
Macular Degeneration
Topical Alprostadil for Female Sexual Arousal Disorder
Started Sep 2004
300 enrolled
Sexual Dysfunction, Physiological
Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV
Started Mar 2004
840 enrolled
Peripheral Arterial Occlusive Disease
Career Relevance
Working on PROSTIN VR PEDIATRIC offers stability in a niche, specialized market but limited growth potential as the product approaches loss of exclusivity. Career mobility will be strongest in hospital relationships, specialty pharmacy channels, and pediatric cardiology networks rather than in high-visibility commercial expansion roles.
Worked on PROSTIN VR PEDIATRIC at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.